Immune cell PD-L1 co-localizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy.
PD-L1 is expressed in tumor cells and immune cells and both have been associated with response to anti-PD-1 axis immunotherapy. Here, we examine the expression of PD-L1 to determine which cell type carries the predictive value of the test. We measured the expression of PD-L1 in multiple immune cells with two platforms and confocal microscopy on three retrospective Yale NSCLC cohorts (425 non-immunotherapy-treated cases and 62 pembrolizumab/nivolumab/atezolizumab-treated cases). The PD-L1 level was selectively measured in different immune cell subsets using two multiplexed QIF panels including CD56 for natural killer (NK) cells, CD68 for macrophages and CD8 for cytotoxic T cells. PD-L1 was significantly higher in macrophages in both tumor and stromal compartment compared to other immune cells. Elevated PD-L1 in macrophages was correlated with high PD-L1 level in tumor as well as CD8 and CD68 level (P<0.0001). High PD-L1 expression in macrophages was correlated with better overall survival (OS; p=0.036 by cell count/ p=0.019 by molecular co-localization) while high PD-L1 expression in tumor cells was not. In nearly 500 NSCLC cases the predominant immune cell type that expresses PD-L1 is CD68+ macrophages. The level of PD-L1 in macrophages is significantly associated with the level of PD-L1 in tumor cells and infiltration by CD8+ T cells, suggesting a connection between high PD-L1 and "hot" tumors. In anti-PD-1 axis therapy treated patients, high levels of PD-L1 expression in macrophages is associated with longer overall survival and may be responsible for the predictive effect of the marker.